中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

69 records (took 0.023 seconds)

    METHODOLOGY FOR ANALYSIS OF SEQUENCE VARIATIONS WITHIN THE HCV NS3/4A GENOMIC REGION
    2.
    发明申请
    METHODOLOGY FOR ANALYSIS OF SEQUENCE VARIATIONS WITHIN THE HCV NS3/4A GENOMIC REGION 审中-公开
    用于分析HCV NS3 / 4A基因组区域中序列变异的方法

    公开(公告)号：WO2008046923A2

    公开(公告)日：2008-04-24

    申请号：PCT/EP2007/061242

    申请日：2007-10-19

    Applicant: INNOGENETICS N.V. ,  SABLON, Erwin ,  LIBBRECHT, Evelien

    Inventor： SABLON, Erwin ,  LIBBRECHT, Evelien

    IPC: C12Q1/70

    CPC classification number: C12Q1/707

    Abstract: The current invention relates to a standardized method for amplification o f an HCV NS3/4A or NS3 nucleic acid fragment of any one of HCV genotypes 5 to 6 or HCV genotype 1 as a tool for analysis of sequence variations that may be correlated with 5 HCV drug resistance.

    Abstract translation: 本发明涉及用于扩增HCV基因型5至6或HCV基因型1中任一HCV HCV NS3 / 4A或NS3核酸片段的标准化方法，作为用于分析可能与5种HCV药物相关的序列变异的工具 抵抗性。

    COMBINATIONS OF MARKERS FOR INCREASED ACCURACY OF DIAGNOSIS OF RHEUMATOID ARTHRITIS
    3.
    发明申请
    COMBINATIONS OF MARKERS FOR INCREASED ACCURACY OF DIAGNOSIS OF RHEUMATOID ARTHRITIS 审中-公开

    公开(公告)号：WO2008009732A3

    公开(公告)日：2008-01-24

    申请号：PCT/EP2007/057489

    申请日：2007-07-19

    Applicant: INNOGENETICS N.V. ,  NUYTINCK, Lieve

    Inventor： NUYTINCK, Lieve

    IPC: C12Q1/68

    Abstract: The present invention relates to methods for identifying a subject having, at risk of having or at risk of developing rheumatoid arthritis which comprise detecting the combined presence of a nucleic acid variant in a ficolin gene and another marker for rheumatoid arthritis in a subject. The invention further provides tools and kits for performing these methods and the use of these methods in differential diagnosis of arthritis and personalised therapy.

    DETECTION, IDENTIFICATION AND DIFFERENTIATION OF SERRATIA SPECIES USING THE SPACER REGION
    5.
    发明申请
    DETECTION, IDENTIFICATION AND DIFFERENTIATION OF SERRATIA SPECIES USING THE SPACER REGION 审中-公开
    使用间隔区域检测，鉴定和分类的SERRATIA物种

    公开(公告)号：WO2006035062A1

    公开(公告)日：2006-04-06

    申请号：PCT/EP2005/054913

    申请日：2005-09-29

    Applicant: INNOGENETICS N.V. ,  ROCHE DIAGNOSTICS GMBH ,  JANNES, Geert ,  MIJS, Wouter ,  EMRICH, Thomas ,  HABERHAUSEN, Gerd

    Inventor： JANNES, Geert ,  MIJS, Wouter ,  EMRICH, Thomas ,  HABERHAUSEN, Gerd

    IPC: C12Q1/68

    CPC classification number: C12Q1/689 ,  Y10T436/143333

    Abstract: The present invention relates to new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region, between the 16S and 23 S rRNA genes, to be used for the specific detection and/or identification of Serratia species, in particular of Serratia marcescens, Serratia ficaria and/or Serratia fonticola, in a biological sample. The present invention relates also to a method for the specific detection and/or identification of Serratia species, in particular Serratia marcescens, Serratia ficaria and/or Serratia fonticola, using said new nucleic acid sequences derived from the ITS region. It relates also to nucleic acid primers to be used for the amplification of said spacer region of Serratia species in a sample.

    Abstract translation: 本发明涉及来自16S和23S rRNA基因之间的ITS（内转录间隔区）的新核酸序列，用于特异性检测和/或鉴定沙雷氏菌属，尤其是粘质沙雷氏菌， 在沙门氏菌属和/或沙雷氏菌中，在生物样品中。 本发明还涉及使用来自ITS区域的所述新的核酸序列特异性检测和/或鉴定沙雷氏菌属物种，特别是沙雷氏菌属沙雷氏菌属，沙雷氏菌属和/或沙雷氏菌属的方法。 它还涉及用于扩增样品中沙雷氏菌属物种的所述间隔区的核酸引物。

    DETECTION, IDENTIFICATION AND DIFFERENTIATION OF EUBACTERIAL TAXA USING A HYBRIDIZATION ASSAY
    7.
    发明申请
    DETECTION, IDENTIFICATION AND DIFFERENTIATION OF EUBACTERIAL TAXA USING A HYBRIDIZATION ASSAY 审中-公开
    使用杂交测定法检测，鉴定和鉴定非特异性毒素

    公开(公告)号：WO2004053156A1

    公开(公告)日：2004-06-24

    申请号：PCT/EP2003/013905

    申请日：2003-12-08

    Applicant: INNOGENETICS N.V. ,  ROCHE DIAGNOSTICS GMBH ,  DE HENAU, Hilde ,  VAN CROMBRUGGEN, Joachim ,  JANNES, Geert ,  HABERHAUSEN, Gerd ,  EMRICH, Thomas

    Inventor： DE HENAU, Hilde ,  VAN CROMBRUGGEN, Joachim ,  JANNES, Geert ,  HABERHAUSEN, Gerd ,  EMRICH, Thomas

    IPC: C12Q1/68

    CPC classification number: C12Q1/689

    Abstract: The present invention relates to a method for the specific detection and/or identification of Enterococcus species, in particular Enterococcus faecalis and/or Enterococcus faecium, using new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region.The present invention relates also to said new nucleic acid sequences derived from the ITS region, between the 16S and 23S ribosomal ribonucleic acid (rRNA) or rRNA genes, to be used for the specific detection and/or identification of Enterococcus species, in particular of Enterococcus faecalis and/or Enterococcus faecium, in a biological sample.It relates also to nucleic acid primers to be used for the amplification of said spacer region of Enterococcus species in a sample.

    Abstract translation: 本发明涉及使用源自ITS（内转录间隔区）的新核酸序列来特异性检测和/或鉴定肠球菌属物种，特别是粪肠球菌和/或屎肠球菌的方法。本发明还涉及 对来自ITS区域的所述新的核酸序列，16S和23S核糖核糖核酸（rRNA）或rRNA基因之间，用于特异性检测和/或鉴定肠球菌属物种，特别是粪肠球菌和/或 生物样品中的屎肠球菌。还涉及用于在样品中扩增肠球菌属物种的所述间隔区的核酸引物。

    MONOCLONAL ANTIBODY ANTI-C3-2 DIRECTED AGAINST THE THIRD COMPONENT OF COMPLEMENT (C3) AND ITS USE IN METHODS TO INHIBIT COMPLEMENT ACTIVATION
    8.
    发明申请
    MONOCLONAL ANTIBODY ANTI-C3-2 DIRECTED AGAINST THE THIRD COMPONENT OF COMPLEMENT (C3) AND ITS USE IN METHODS TO INHIBIT COMPLEMENT ACTIVATION 审中-公开
    单克隆抗体抗C3-2指导第三方补充组件（C3）及其用于抑制补充激活的方法

    公开(公告)号：WO2004031240A1

    公开(公告)日：2004-04-15

    申请号：PCT/EP2003/010989

    申请日：2003-10-03

    Applicant: INNOGENETICS N.V. ,  SANQUIN BLOOD SUPPLY FOUNDATION AMSTERDAM ,  DE WINTER, Hilde ,  BUYSSE, Marie-Ange ,  HACK, Erik

    Inventor： DE WINTER, Hilde ,  BUYSSE, Marie-Ange ,  HACK, Erik

    IPC: C07K16/18

    CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K2317/24

    Abstract: The invention describes a method to inhibit inflammatory reactions in vivo, more specifically the activation of the complement system. The invention consists of the identification and inhibition of a novel functional domain on the native third component of complement, C3, which domain is essential for the activation of C3. Inhibition of conformational changes of the identified domain prevents the activation of C3, and hence the generation of biologically active peptides such as C3a and C5a, and the formation of membrane attack complexes. The preferred inhibitor is a monoclonal antibody (mAb), a humanised monoclonal antibody or a human monoclonal antibody against the identified domain, or functional fragments derived therefrom, or peptides complementary to the identified domain

    Abstract translation: 本发明描述了抑制体内炎症反应的方法，更具体地说是补体系统的活化。 本发明包括鉴定和抑制补体C3的天然第三成分上的新功能结构域，该结构域对于C3的活化是必需的。 所鉴定结构域的构象变化的抑制可以防止C3的活化，从而导致生物活性肽如C3a和C5a的产生以及膜攻击复合物的形成。 优选的抑制剂是针对鉴定的结构域的单克隆抗体（mAb），人源化单克隆抗体或人单克隆抗体或由其衍生的功能片段或与所鉴定的结构域互补的肽

    NEW HEPATITIS C VIRUS GENOTYPE, AND ITS USE AS PROPHYLACTIC, THERAPEUTIC AND DIAGNOSTIC AGENT
    9.
    发明申请
    NEW HEPATITIS C VIRUS GENOTYPE, AND ITS USE AS PROPHYLACTIC, THERAPEUTIC AND DIAGNOSTIC AGENT 审中-公开
    新型丙型肝炎病毒基因组及其用作预防，治疗和诊断代理

    公开(公告)号：WO2003020970A2

    公开(公告)日：2003-03-13

    申请号：PCT/EP2002/009731

    申请日：2002-08-30

    Applicant: INNOGENETICS N.V. ,  SABLON, Erwin ,  VAN DOORN, Leen-Jan ,  QUINT, Wim

    Inventor： SABLON, Erwin ,  VAN DOORN, Leen-Jan ,  QUINT, Wim

    IPC: C12Q1/68

    CPC classification number: C12Q1/707

    Abstract: The present invention relates to genomic nucleotide sequences and amino acid sequences corresponding to the non-coding and coding region of a new type of HCV. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes sequences. Particularly, the present invention relates to said new HCV type sequences; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the 5' NCR, Core, the E1 and the NS5 regions of the new HCV type. These new HCV sequences are useful to diagnose the presence of HCV type genotypes or serotypes in a biological sample. Moreover, the availability of these new type-specific sequences can increase the overall sensitivity of HCV detection and should also prove to be useful for prophylactic and therapeutic purposes.

    Abstract translation: 本发明涉及对应于新型HCV的非编码区和编码区的基因组核苷酸序列和氨基酸序列。 本发明涉及与已知的HCV类型和亚型序列不同的新的HCV类型和亚型序列。 特别地，本发明涉及所述新型HCV型序列; 它们的制备过程及其在诊断，预防和治疗中的应用。 更具体地说，本发明提供新HCV型5'NCR，核心，E1和NS5区域的新型特异性序列。 这些新的HCV序列可用于诊断生物样品中HCV型基因型或血清型的存在。 此外，这些新型特异性序列的可用性可以提高HCV检测的总体灵敏度，并且还应证明可用于预防和治疗目的。

Patent Agency Ranking